US Stock Market Move | The trial of a new heart disease drug did not meet its primary endpoint, causing Novo Nordisk A/S Sponsored ADR Class B (NVO.US) to plummet nearly 10%.

On Friday, Danish pharmaceutical giant Novo Nordisk A/S Sponsored ADR Class B (NVO.US) opened with a significant drop, declining nearly 10% as of the time of writing. The news came after the company announced that its highly anticipated experimental heart drug ziltivekimab failed to meet its primary endpoint in a large late-stage clinical trial, as it did not significantly reduce the incidence of major adverse cardiovascular events (MACE) compared to a placebo. This key trial failure is undoubtedly another setback for the Danish drugmaker, which is making every effort to regain investor confidence in its R&D pipeline and execution capabilities, especially in the challenging U.S. market. Novo Nordisk A/S Sponsored ADR Class B stated that while the experimental drug ziltivekimab showed some biological activity, it did not a statistically significant reduction in major adverse cardiovascular events. MACE typically includes significant cardiovascular events such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.